阈值增长是否应作为LI-RADS诊断肝细胞癌的主要特征?
本回顾性研究纳入1013个肝局灶性病变,分析LI-RADS v2018中阈值增长作为主要特征对HCC的诊断性能。结果显示阈值增长在非HCC恶性肿瘤中更常见,将其归为辅助特征并以脂肪结节内作为主要特征后,LR-5诊断性能与LI-RADS v2018相当。
要点
- 阈值增长在非HCC恶性肿瘤中更常见,不宜作为HCC主要特征。
- 脂肪结节内更常见于HCC,可考虑作为主要特征替代阈值增长。
- 调整后LR-5敏感度和特异度与LI-RADS v2018相当。
关键影像表现/征象
- 动脉期高强化、廓清和强化包膜在HCC中较非HCC恶性肿瘤更常见(分别为521/616 vs. 18/58、489/616 vs. 19/58、181/616 vs. 5/58,p < 0.001)。
- 阈值增长在非HCC恶性肿瘤中较HCC更常见(11/23 vs. 17/119,p < 0.001)。
- 脂肪结节内在HCC中较非HCC恶性肿瘤更常见(99/616 vs. 2/58,p = 0.010)。
诊断标准与关键数值
- LI-RADS v2018中阈值增长作为主要特征时,LR-5诊断HCC的敏感度为73.2%、特异度为98.2%。
- 将阈值增长归为辅助特征并以脂肪结节内作为主要特征后,LR-5敏感度为73.9%(p = 0.289)、特异度为98.5%(p > 0.999)。
临床应用与阅片要点
- 阅片时应注意阈值增长更常见于非HCC恶性肿瘤,避免据此过度诊断HCC。
- 脂肪结节内更支持HCC诊断,可结合其他LI-RADS特征综合判断。
局限性
- 回顾性研究,存在选择偏倚可能。
- 单中心研究,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Based on the Liver Imaging Reporting and Data System version 2018 (LI-RADS, v2018), this study aimed to analyze LR-5 diagnostic performance for hepatocellular carcinoma (HCC) when threshold growth as a major feature is replaced by a more HCC-specific ancillary feature, as well as the frequency of threshold growth in HCC and non-HCC malignancies and its association with tumor size.
MATERIALS AND METHODS: This retrospective study included treatment-naive patients who underwent gadoxetate disodium-enhanced MRIs for focal hepatic lesions and surgery between January 2009 and December 2016. The frequency of major and ancillary features was evaluated for HCC and non-HCC malignancies, and the LR-category was assessed. Ancillary features that were significantly more prevalent in HCC were then used to either replace threshold growth or were added as additional major features, and the diagnostic performance of the readjusted LR category was compared to the LI-RADS v2018.
RESULTS: A total of 1013 observations were analyzed. Unlike arterial phase hyperenhancement, washout, or enhancing capsule which were more prevalent in HCCs than in non-HCC malignancies (521/616 vs. 18/58, 489/616 vs. 19/58, and 181/616 vs. 5/58, respectively; p < 0.001), threshold growth was more prevalent in non-HCC malignancies than in HCCs (11/23 vs. 17/119; p < 0.001). The mean size of non-HCC malignancies showing threshold growth was significantly smaller than that of non-HCC malignancies without threshold growth (22.2 mm vs. 42.9 mm, p = 0.040). Similar results were found for HCCs; however, the difference was not significant (26.8 mm vs. 33.1 mm, p = 0.184). Additionally, Fat-in-nodule was more frequent in HCCs than in non-HCC malignancies (99/616 vs. 2/58, p = 0.010). When threshold growth and fat-in-nodule were considered as ancillary and major features, respectively, LR-5 sensitivity (73.2% vs. 73.9%, p = 0.289) and specificity (98.2% vs. 98.5%, p > 0.999) were comparable to the LI-RADS v2018.
CONCLUSION: Threshold growth is not a significant diagnostic indicator of HCC and is more common in non-HCC malignancies. The diagnostic performance of LR-5 was comparable when threshold growth was recategorized as an ancillary feature and replaced by a more HCC-specific ancillary feature.
引用
- Park JH, Chung YE, Seo N, et al. Should Threshold Growth Be Considered a Major Feature in the Diagnosis of Hepatocellular Carcinoma Using LI-RADS? Korean J Radiol. 2021. PMID: 34269533. doi:10.3348/kjr.2020.1341
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。